一心堂药业集团股份有限公司 关于全资子公司鸿翔中药有限公司 竞得土地使用权的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、基本情况概述 一心为民全心服务 股票代码：002727 股票简称：一心堂 公告编号：2023-074 号 一心堂药业集团股份有限公司（以下简称"公司"）于 2023 年 6 月 20 日召开第六 届董事会第三次临时会议审议通过《关于同意公司全资子公司鸿翔中药有限公司与昆明 经济技术开发区管理委员会签订项目投资合作协议的议案》，同意全资子公司鸿翔中药 有限公司（以下简称"鸿翔中药"）与昆明经济技术开发区管理委员会（以下简称"经 开区管委会"）签订《项目投资合作协议》。鸿翔中药拟在昆明市经开区投资建设中药 饮片产能扩建项目，项目总投资 4 亿元，新建数字化智能制造中药饮片生产基地，建设 中药材、中药饮片数字化物流配送中心及第三方检验平台业务服务中心。经开区管委会 根据《中国（云南）自由贸易试验区昆明片区管理委员会昆明经济技术开发区管理委员 会关于印发促进产业高质量发展系列政策的通知》（昆自贸管〔2022〕1 号），于 2023 ...

股票代码：002727 股票简称：一心堂 公告编号：2023-072 号 一心堂药业集团股份有限公司 关于全资子公司上海鸿翔一心堂药业有限公司收购上海康君阁大 药房连锁有限公司 43 家门店资产及其存货的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一心为民全心服务 特别提示： （一）药品安全风险 公司所处的医药流通行业对药品安全的要求非常高，如果质量控制的某个环节出现 疏忽，影响药品安全，本公司将要承担相应的责任。同时，药品安全事故的发生将对本 公司的品牌和经营产生不利影响。自公司成立以来，对所有销售药品质量均进行严格的 把关，并根据《中华人民共和国药品管理法》、《中华人民共和国药品生产质量管理规 范》和《中华人民共和国药品经营质量管理规范》制定了《首营企业和首营品种审核制 度》、《药品进货管理程序》、《商品验收管理制度》、《供应商评审管理办法》、《三 级质量管理办法》、《质检抽（送）样管理办法》、《质量投诉管理办法》等一整套比 较完备的制度，在日常经营过程中，严格按照相关制度的规定执行，对所生产、采购药 品均进行严格的质量控制。但公司在对所采购药品 ...

Financial Performance - As of June 30, 2023, revenue reached 8.675 billion CNY, a year-on-year increase of 8.92% [2] - Net profit attributable to shareholders was 504 million CNY, up 20.64% year-on-year [2] - Operating cash flow was 682 million CNY, indicating stable cash flow [2] - Total assets amounted to 15.866 billion CNY, with a net asset value of 7.8 billion CNY and a debt-to-asset ratio of 50.82% [2] Store Operations - The number of direct-operated stores reached 9,569, with a net increase of 363 stores during the reporting period [3] - Store traffic has recovered to pre-pandemic levels, showing nearly a 10% increase [3] - The majority of stores (5,269) are located in Yunnan, accounting for over half of the total [3] Business Model Innovations - Integration of new business lines such as lottery, maternal and infant products, and beauty products has shown positive results [3] - The company is experimenting with new operational models, including the "drug-diagnosis" store format to adapt to policy changes [3] - The company is focusing on enhancing logistics efficiency by planning a logistics base in Chengdu [4] Chronic Disease Management - Chronic disease customers represent the most stable clientele, with a quarterly visit frequency and average spending of 200-300 CNY per visit [5] - The gross margin for chronic disease products, particularly prescription drugs, is maintained below 10% [5] Regional Performance - The Sichuan-Chongqing region is expected to achieve a retail scale of approximately 2.5 billion CNY in 2023, contributing significantly to store expansion [8] - Other regions like Guangxi and Shanxi are also showing promising growth, with expected retail scales exceeding 1 billion CNY [8] Digital Transformation - The company is investing 360 million CNY in a five-year digital transformation plan, aiming to enhance operational efficiency and customer experience [12] - A new ERP system has been implemented, with plans for further upgrades in customer relationship management and inventory systems [12] Policy Impact and Future Outlook - The company is adapting to healthcare reforms aimed at improving accessibility and affordability, while also expanding its product offerings to attract a broader customer base [6] - The impact of ongoing medical anti-corruption measures on business operations is being closely monitored, with expectations for gradual improvements in prescription flow [13]

投资者关系活动记录表 证券代码：002727 证券简称：一心堂 1 一心堂药业集团股份有限公司投资者关系活动记录表 编号：TG202308-001 | --- | --- | |-----------------------------|-----------------------------------------------------------------------------------------------------| | | | | | ■特定对象调研□分析师会议 | | | □媒体采访 业绩说明会下 | | 投资者关系活动类别 | □新闻发布会 路演活动 | | | □现场参观 | | | ■其他（电话会议） | | 参与单位名称及人员 | 东北证券 刘宇腾 叶倩 、进门财经 吴林森、汇添富 李泽 昱、卓晔基金 张帅等投资者 63 人 | | 姓名 | | | 时间 | 2023 年 8 月 30 日 15:00-16:00 | | 地点 | 一心堂药业集团股份有限公司总部 | | 公司接待人员姓名 | 副总裁兼董事会秘书李正红、证券总监兼证券事务代表 肖 冬磊 | | 投资者关系活动 ...

Dividend and Share Capital Policies - The company plans not to distribute cash dividends, issue bonus shares, or convert capital reserve into share capital[10] Risk Factors - The company's business operations are subject to various risk factors, including macroeconomic and market risks, as well as risks related to its main business[15] Fixed Assets and Depreciation - The company's fixed assets are depreciated using the straight-line method with varying depreciation periods and rates for different categories such as buildings, machinery, electrical equipment, transportation equipment, and tools[28] Investment Properties - The company's investment properties are accounted for based on their acquisition cost, construction cost, or other relevant costs, with subsequent expenditures capitalized if they meet the recognition criteria[26] Long-term Equity Investments - The company's long-term equity investments are initially measured at cost, with adjustments made for additional investments or disposals, and dividends or profits recognized as investment income[22] Financial Instruments - The company's financial instruments are classified and measured at fair value, with changes in fair value recognized in other comprehensive income for certain categories[17] - The company employs an expected credit loss model to assess financial instrument impairment, considering historical data and macroeconomic factors[88] - The company determines the fair value of financial instruments by referencing observable market prices and deducting incremental costs directly attributable to the disposal of the asset[89] Held-for-Sale Assets - The company's held-for-sale assets are measured at the lower of their carrying amount and fair value less costs to sell, with any impairment losses recognized in the current period[19] Business Combinations - The company's business combinations are accounted for using the acquisition method, with the cost of the combination determined based on the fair value of the assets given, liabilities incurred, and equity instruments issued[21] - In business combinations, assets and liabilities acquired in a business combination under common control are measured at their carrying amounts at the date of acquisition. The difference between the carrying amount of net assets acquired and the consideration paid is adjusted against capital reserves[54] - The initial recognition amount of the consideration involves contingent consideration, which is included in the merger cost at its fair value on the acquisition date. Adjustments to contingent consideration within 12 months post-acquisition due to new evidence will adjust the goodwill[57] Subsidiaries and Associates - The company's subsidiaries and associates are accounted for using the equity method, with adjustments made for any differences between the carrying amount and the share of net assets[24] Construction in Progress - The company's construction in progress is accounted for based on the actual costs incurred, with any necessary adjustments made for impairments or changes in circumstances[30] Borrowing Costs - Borrowing costs include interest on borrowings, amortization of discounts or premiums, ancillary costs, and exchange differences arising from foreign currency borrowings. Costs directly attributable to the acquisition, construction, or production of qualifying assets are capitalized when expenditures are incurred, borrowing costs are incurred, and activities necessary to prepare the asset for its intended use or sale have begun. Capitalization ceases when the asset is ready for its intended use or sale[31] Biological Assets - Consumable biological assets are measured at the lower of cost and net realizable value at the balance sheet date. If the factors causing impairment have reversed, the impairment loss is reversed up to the amount previously recognized, and the reversal is recognized in profit or loss[32] Intangible Assets - The company reviews the useful lives and amortization methods of finite-lived intangible assets at the end of each period. Changes are treated as changes in accounting estimates[33] Contract Liabilities - Contract liabilities represent the company's obligation to transfer goods or services to customers for which it has received or is entitled to receive consideration. These are recognized when the company has an unconditional right to payment or when the customer has paid[39] Post-Employment Benefits - Post-employment benefits are classified as defined contribution plans or defined benefit plans. Contributions to defined contribution plans are recognized as expenses or capitalized as part of asset costs during the period when employees render services[40] Income Taxes - The company uses the balance sheet liability method to account for income taxes. Deferred tax assets and liabilities are recognized for temporary differences, except for certain transactions that do not affect accounting profit or taxable income[48] - The company reviews the carrying value of deferred tax assets at each balance sheet date. If future taxable income is unlikely to cover the deferred tax asset benefits, the carrying value is reduced[70] Operating Leases - For operating leases, the company recognizes lease payments on a straight-line basis over the lease term. Variable lease payments not included in the lease receivable are recognized in profit or loss when incurred[53] Step-by-Step Non-Controlling Acquisitions - For step-by-step non-controlling acquisitions, the accounting treatment depends on whether the transactions are considered a "package deal." If not, the initial investment cost in individual financial statements is the sum of the pre-acquisition equity book value and the new investment cost on the acquisition date[58] Long-term Deferred Expenses - Long-term deferred expenses are recorded at actual cost and amortized evenly over the project's benefit period[59] Revenue Recognition - The company's pharmaceutical wholesale business recognizes revenue when goods are delivered and signed for by customers, with no significant financing component involved[64] Government Subsidies - Government subsidies are recognized and measured based on specific criteria, including policy-related preferential loan interest subsidies, which may reduce deferred income or be directly recorded in current profits[65] Share Capital and Equity - The company issued 6,026,392 convertible bonds with a total face value of 602,639,200 yuan in 2019, which increased the total share capital by 22,420,714 shares due to conversions by November 2, 2020[73] - In 2020, the company granted 5,122,000 restricted shares to 91 incentive recipients at a price of 10.42 yuan per share, raising a total of 53,371,240 yuan[73] - In 2022, the company approved the release of 343,200 restricted shares for 30 incentive recipients and 1,494,600 restricted shares for 86 recipients, meeting the conditions for the first and second unlocking periods, respectively[74] - The company repurchased and canceled 110,000 restricted shares from 6 incentive recipients who left the company, rendering them ineligible for incentives[75] - An additional 47,100 restricted shares were repurchased and canceled from 6 ineligible incentive recipients[76] - 23.46 million restricted shares were unlocked for 25 incentive recipients as the second lock-up period ended[77] - 146.31 million restricted shares were unlocked for 82 incentive recipients as the third lock-up period ended[77] - The company's total share capital as of June 30, 2023, was RMB 596,023,425.00[80] - The company's total equity at the end of the first half of 2023 was RMB 5,979,405,523.54, with a capital reserve of RMB 2,154,085,294.17 and undistributed profits of RMB 2,867,975,073.18[100] - The company's comprehensive income for the first half of 2023 was RMB 319,671,420.80, contributing to the increase in total equity[96] - The company allocated RMB 238,409,370.00 for profit distribution to shareholders during the first half of 2023[96] - The company's capital reserve increased by RMB 411,527.85 due to owner contributions and capital reductions[96] - The company's total equity at the beginning of the period was RMB 5,242,192,544.41, with a net increase of RMB 199,116,891.65 during the period[103] - Comprehensive income for the period amounted to RMB 348,662,381.62[103] - The company repurchased and canceled 10,000 restricted shares due to the disqualification of one incentive object, with a total repurchase amount of RMB 110,000.00[108] - The company's total equity at the end of the period was RMB 5,441,309,436.06[106] - The company granted 878,000 restricted shares to 31 incentive objects at a price of RMB 19.08 per share, raising RMB 16,752,240.00[108] - The company's capital reserve increased by RMB 5,873,359.53 during the period[103] - The company's undistributed profit increased by RMB 169,808,224.12 during the period[103] - The company's inventory shares decreased by RMB 23,545,308.00 during the period[103] - The company's total equity increased by RMB 29,308,667.53 due to owner contributions and capital reductions[103] - The company's profit distribution to owners (or shareholders) amounted to RMB -178,854,157.50[103] Business Operations - The company operates in a wide range of sectors including pharmaceutical wholesale and retail, medical device sales, internet services, and more[81] Inventory Valuation - Inventory is measured at the lower of cost or net realizable value, with provisions made for obsolete and slow-moving inventory[88] - The company's inventory valuation and impairment provisions are influenced by factors such as the purpose of holding inventory and post-balance sheet events[89] Impairment Testing - The company conducts impairment tests for non-current assets, including intangible assets with indefinite useful lives, when there are indications of potential impairment[89] Accounts Receivable - The accounts receivable for wholesale transactions at the end of the period amounted to RMB 30,133,037.37, with a bad debt provision of RMB 1,921,772.53, representing a 6.38% provision rate[171] - The total accounts receivable at the end of the period were RMB 111,022,795.57, with a total bad debt provision of RMB 13,807,755.74, representing a 12.44% provision rate[171] - The accounts receivable for medical insurance payments at the end of the period amounted to RMB 471,136.49, with a bad debt provision of RMB 358,066.70, representing a 76.00% provision rate[171] - The accounts receivable for commercial insurance at the end of the period amounted to RMB 80,147,664.70, with a bad debt provision of RMB 11,430,115.10, representing a 14.26% provision rate[171] - The accounts receivable for payment settlement platforms at the end of the period amounted to RMB 270,957.01, with a bad debt provision of RMB 97,801.41, representing a 36.09% provision rate[171] - The total bad debt provision for the period was RMB 19,182,300.84, with a total recovery or reversal of RMB 39,374.44[171] - Accounts receivable totaled 1,711,746,059.16 yuan, with 1,550,002,965.01 yuan (90.5%) within 1 year, 114,272,080.88 yuan (6.7%) between 1-2 years, 37,550,646.72 yuan (2.2%) between 2-3 years, and 9,920,366.55 yuan (0.6%) over 3 years[188] - The top 5 customers accounted for 13.99% of total accounts receivable, with Customer A having the largest balance of 69,332,539.13 yuan (4.05%)[191] Cash and Cash Equivalents - The company's cash and cash equivalents decreased from 3,511,631,958.78 yuan to 3,110,893,151.81 yuan, with restricted funds amounting to 524,436,957.46 yuan due to bill acceptance guarantees[179] Bank Acceptance Bills - Bank acceptance bills increased significantly from 913,200.00 yuan to 3,968,955.57 yuan[180] Subsidiaries and Consolidated Financial Statements - The company has 47 subsidiaries included in the consolidated financial statements as of June 30, 2023[196] - The financial statements are prepared in accordance with Chinese Accounting Standards and the disclosure requirements of the China Securities Regulatory Commission[197] Financial Assets - The company's financial assets measured at fair value through profit or loss remained unchanged at 8,356,564.57 yuan, related to the acquisition of Sichuan Bencaotang Pharmaceutical Co., Ltd[179] Actual Controller - The company's actual controller is Mr. Ruan Hongxian, a natural person[195] Going Concern - The company assessed that there are no significant factors affecting its ability to continue as a going concern for the next 12 months[199] Accounting Policies and Estimates - The company's accounting policies and estimates cover financial instruments, financial asset impairment, and revenue recognition, among others[200] Tax Incentives and Rates - Yunnan Hongxiang Traditional Chinese Medicine Technology Co., Ltd. enjoys tax exemption and a 25% corporate income tax rate[117] - Yunnan Dianxian Transportation Co., Ltd. benefits from small and micro enterprise tax incentives, with a reduced tax rate of 20% on taxable income between 1 million and 3 million yuan[123] - Guangxi Hongxiang Yixintang Pharmaceutical Co., Ltd. continues to enjoy the Western Development tax incentive, with a reduced corporate income tax rate of 15%[124] - Sichuan Hongxiang Yixintang Pharmaceutical Chain Co., Ltd. and Guizhou Hongxiang Yixintang Pharmaceutical Chain Co., Ltd. both benefit from the Western Development tax incentive, with a reduced corporate income tax rate of 15%[124][126] - Yunnan Hongyun Pharmaceutical Supply Chain Co., Ltd. has a corporate income tax rate of 15%[117] - Yunnan Sancai Space Advertising Co., Ltd. and Shanxi Hongxiang Yixintang Pharmaceutical Co., Ltd. both have a corporate income tax rate of 25%[117] - Yunnan Yunshang Youpin E-commerce Co., Ltd. and Yunnan Xingjiyuan Biotechnology Co., Ltd. both have a corporate income tax rate of 25%[117] - Yunnan Fuling Industrial Co., Ltd. and Yunnan Yuntianma Co., Ltd. both enjoy tax exemption and a 25% corporate income tax rate[118] - Yunnan Yunxian Medicinal Materials Co., Ltd. benefits from tax incentives as per the relevant regulations[118] - Yunnan Hongyun Pharmaceutical Service Co., Ltd. has a corporate income tax rate of 25%[117] - Yunnan Hongyun Pharmaceutical Supply Chain Co., Ltd. enjoys a reduced corporate income tax rate of 15% under the Western Development preferential tax policy for the first half of 2023[127] - Yiyun Medical Industry Development (Yunnan) Co., Ltd. benefits from a reduced corporate income tax rate of 20% on taxable income up to 1 million yuan and 25% on taxable income between 1-3 million yuan for the first half of 2023[131] - Mianyang Bencaotang Pharmacy Chain Co., Ltd. qualifies as a small and low-profit enterprise, enjoying a reduced corporate income tax rate of 20% on taxable income up to 1 million yuan and 50% on taxable income between 1-3 million yuan[134] - Yunnan Hongxiang Traditional Chinese Medicine Technology Co., Ltd. is exempt from corporate income tax on profits from primary agricultural product processing and applies a 25% tax rate on non-primary processing profits for the first half of 2023[148] - Small-scale VAT taxpayers with monthly sales below 100,000 yuan are exempt from VAT, while those with higher sales enjoy a reduced VAT rate of 1% instead of 3% from January 1, 2023, to December 31, 2027[145] - Yunnan Dianxian Transportation Co., Ltd. qualifies for tax incentives under the national encouraged industries policy, specifically for "highway container and van transportation," allowing self-assessment and tax reduction benefits[149] - Sichuan Hongxiang Yixintang Pharmaceutical Chain Co., Ltd. enjoys a reduced corporate income tax rate of 15% under the Western Development Strategy, effective from 2021 to 2030[150] - Guizhou Hongxiang Yixintang benefits from a 15% corporate income tax rate due to its alignment with the "unified distribution and sales network construction" under the Western Development Strategy[151] - Chongqing Hongxiang Yixintang Pharmaceutical Co., Ltd. continues to apply a 15% corporate income tax rate for the first half of 2023 under the Western Development Strategy[153] - Sichuan Yixintang Pharmaceutical Chain Co., Ltd. maintains a 15% corporate income tax rate for the first half of 2023 under the Western Development Strategy[154] - Hongxiang Traditional Chinese Medicine Technology Co., Ltd. exempts income tax on its agricultural primary processing business, while applying a 25% tax rate to non-agricultural processing income[155] - Hainan Hongxiang Yixintang Pharmaceutical Chain Co., Ltd. benefits from a 15% corporate income tax rate from 2020 to 2024 under the Hainan Free Trade Port policy[156] - Yunnan Traditional Chinese Medicine Co., Ltd. exempts income tax on its agricultural primary processing business and applies a 25% tax rate to non-agricultural processing income[158] - Yiyun Medical Industry Development (Yunnan) Co., Ltd. enjoys reduced corporate income tax rates for small and micro-profit enterprises, with specific reductions based on taxable income thresholds[158] - Guang'an Changyu Pharmaceutical Co., Ltd. qualifies as a small and micro-profit enterprise, enjoying a reduced corporate income tax rate of 20% on taxable income up to RMB 1 million, with 25% of the income included in taxable income, and 50% of the income included for taxable income between RMB 1 million and RMB 3 million[160] - Yunnan Yunxian Medicinal Materials Co., Ltd. has opted for the small and micro-profit enterprise tax优惠政策, benefiting from a reduced corporate income tax rate of 20% on taxable income up to RMB 1 million, with 25% of the income included in taxable income, and 25% of the income included for taxable income between RMB 1 million and RMB 3 million for the period from January 1, 2022, to December 31, 2024[162] - Yunnan Fuling Industrial Co., Ltd. qualifies as a small and micro-profit enterprise, enjoying a reduced corporate income tax rate of 20% on taxable income up to RMB 1 million, with 25% of the income included in taxable income, and 25% of the income included for taxable income between RMB 1 million and RMB 3 million for the period from January 1, 2022, to December 31, 2024[174] - Yunnan Yuntianma Co., Ltd. qualifies as a small and micro-profit enterprise, enjoying a reduced corporate income tax rate of 20% on taxable income up to RMB 1 million, with 25% of the income included in taxable income, and 25% of the

经审阅，我们认为：报告期内，公司募集资金的存放与使用情况符合中国证 监会、深圳证券交易所关于上市公司募集资金存放和使用的相关规定，不存在募 集资金存放和使用违规的情形。 公司《2023年上半年募集资金存放与实际使用情况的专项报告》的编制符合 相关法律、法规的规定，真实、客观反映了公司2023年上半年募集资金存放与实 际使用情况，2023年上半年公司募集资金的存放与使用符合中国证监会、深圳证 券交易所关于上市公司募集资金存放和使用的相关规定，不存在募集资金存放和 使用违规的情形。 一心堂药业集团股份有限公司 独立董事关于第六届董事会第三次会议 相关事项的独立意见 根据《深圳证券交易所股票上市规则》、《深圳证券交易所上市公司自律监 管指引第 1 号——主板上市公司规范运作》、《上市公司独立董事规则》、《公 司章程》等相关法律法规的规定，作为一心堂药业集团股份有限公司（以下简称 "公司"）的独立董事，对公司第六届董事会第三次会议议案进行了认真审议， 并对以下相关事项基于独立判断，发表意见如下： 一、《关于公司募集资金专项报告——2023 年上半年募集资金存放与实际使用 情况专项报告的议案》的独立意见 独立董事签字： ...

一心为民全心服务 股票代码：002727 股票简称：一心堂 公告编号：2023-067 号 一心堂药业集团股份有限公司 第六届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 一心堂药业集团股份有限公司（以下称"公司"）第六届董事会第三次会议于 2023 年 8 月 29 日 10 时以现场及通讯表决方式召开，本次会议于 2023 年 8 月 17 日通过邮件 及书面形式发出通知。本次会议应出席会议的董事为9人，实际出席会议的董事为9人。 公司监事及非董事高级管理人员列席了会议。本次会议的召开符合有关法律、行政法规、 部门规章、规范性文件和《公司章程》的规定。 会议由阮鸿献先生主持。与会董事逐项审议了有关议案并做出决议如下。 二、董事会会议审议情况 1．审议通过《关于 2023 年半年度报告全文及摘要的议案》 《关于公司2023年半年度报告全文》详见公司指定信息披露媒体巨潮资讯网 （www.cninfo.com.cn）。并批准 2023年半年度财务报告对外报出。 《2023 年半年度报告摘要》详见公司指定信息披露 ...

股票代码：002727 股票简称：一心堂 公告编号：2023-066 号 一心为民 全心服务 一心堂药业集团股份有限公司 第六届监事会第三次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 一心堂药业集团股份有限公司（以下简称"公司"）第六届监事会第三次会议于 2023 年 8 月 29 日 9 时整在公司会议室召开，本次会议于 2023 年 8 月 17 日通过邮件和书面 形式发出通知。本次会议应出席会议的监事为 3 人，实际出席会议的监事为 3 人。本次 会议的召开符合有关法律、行政法规、部门规章、规范性文件和《公司章程》的规定。 会议由冯萍女士主持。与会监事逐项审议了有关议案并做出决议如下。 二、监事会会议审议情况 1．审议通过《关于 2023 年半年度报告全文及摘要的议案》 经审核，监事会认为董事会编制和审议一心堂药业集团股份有限公司 2023 年半年 度报告的程序符合法律、行政法规及中国证监会的规定，报告内容真实、准确、完整地 反映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 《公司 2023 年 ...

一心堂药业集团股份有限公司关于募集资金 2023 年半年度存放与实际使用情况的专项报告 一心堂药业集团股份有限公司 董事会关于 2023 年半年度募集资金 存放与实际使用情况的专项报告 根据中国证监会发布的《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管 要求（2022 年修订）》和深圳证券交易所发布的《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等有关规定，一心堂药业集团股份有限公司（以下简称"公司"或"本 公司"）董事会编制了截至 2023 年 6 月 30 日止的募集资金半年度存放与实际使用情况的专项报 告。 一、募集资金基本情况 经中国证券监督管理委员会于 2018 年 10 月 23 日出具的《关于核准云南鸿翔一心堂药业（集 团）股份有限公司公开发行可转换公司债券的批复》（证监许可［2018］2160 号）核准，一心 堂药业集团股份有限公司于 2019年4月 19日向社会公众公开发行面值不超过 60,263.92万元的可 转换公司债券，每张面值 100 元，按面值平价发行，发行总额 60,263.92 万元。上述募集资金总 额扣除承销费用人民币 700.00 ...

| 总计 | —— | —— | —— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | —— | —— | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 上市公司核 | 2023 年 | 2023 年半 年度往来 | 2023 年 半年度往 | 2023 年 | 2023 年 | | 往来性质 | | 其它关联资 | 资金往来方名称 | 往来方与上市公司的 | 算的会计科 | 期初往来 | 累计发生 | 来资金的 | 半年度偿 | 半年度期 | 往来形成 | （经营性往 | | 金往来 | | 关联关系 | | | | | 还累计发 | 末往来资 | 原因 | 来、非经营 | | | | | 目 | 资金余额 | 金额（不 | 利息（如 | 生额 | 金余额 | | 性往来） | | | | | | | 含利息） | 有） | | | | | | | 成都锦华药业有限 | 实际控制人阮鸿献投 | 其他应收款 | 51.18 | 49.34 | | 23.98 | 76.54 | ...